Paper - WANFANG MED ONLINE

You Position: Home > Paper

Quantitative analysis and its application of dynamic contrast-enhanced MRI on prostate cancer

( views:510, downloads:838 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF RADIOLOGY

Issue:: 5

DOI:: 10.3760/cma.j.issn.1005-1201.2011.05.023

Key Word:: No keyword available

Abstract： @@ 前列腺癌是老年男性最常见的恶性肿瘤之一,在西方国家位居男性恶性疾病发病率之首[1].近年来前列腺癌在亚洲国家的发病率也呈明显上升趋势,成为威胁老年男性健康的重要疾病之一[2].随着MR成像检查技术的发展,MRI已成为前列腺癌早期诊断和分期最有效的影像手段.

Reference

[1]倪新初,沈钧康,陆之安,等.前列腺癌与良性前列腺增生症的MR动态增强与血管生成的相关性研究[J].2005,(1).
[2]李新民,王霄英,郭雪梅,等.前列腺癌的MR波谱成像中体线圈与直肠内线圈的比较[J].2009,(11).
[3]张兴伟,周康荣,陈祖望.快速序列动态增强MRI对前列腺癌的诊断价值[J].2000,(6).
[4]叶锦棠,郭雪梅,王霄英,等.MR波谱分析对前列腺癌诊断效能的研究[J].2009,(6).
[5]史浩,武乐斌,丁红宇,等.MR动态增强、扩散成像和波谱分析在前列腺癌诊断中的价值[J].2006,(7).
[6]Macura KJ,Bonekamp D.Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate.[J].2008,19(6).
[7]Evans AJ,van der Kwast TH,Langer DL.Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.[J].2009,30(2).
[8]Vigneron DB,Zaloudek CJ,Forstner R,etc.Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images.[J].1995,195(2).
[9]Nguyen T,Brown R,Spincemaille P,etc.In vivo quantification of contrast agent concentration using the induced magnetic field for time-resolved arterial input function measurement with MRI.[J].2008,35(12).
[10]Macura KJ.Multiparametric magnetic resonance imaging of the prostate: current status in prostate cancer detection, localization, and staging.[J].2008,43(4).
[11]Boltze C,Schmuecking M,Geyer H.Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?[J].2009,85(9).
[12]Roberto Alonzi,Clare Allen,Anwar R. Padhani.Dynamic contrast enhanced MRI in prostate cancer[J].2007,63(3).
[13]Schlemmer HP.Dynamic Magnetic Resonance Tomography and Proton Magnetic Resonance Spectroscopy of Prostate Cancers in Rats Treated by Radiotherapy.[J].2004,39(1).
[14]Hulsbergen Van De Kaa CA,Huisman HJ,Blickman JG,etc.Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.[J].2003,229(1).
[15]Xu J,Murray T,Siegel R,etc.Cancer statistics, 2007.[J].2007,57(1).
[16]Jackson AS,Fisher C,Bailey MJ,etc.Dynamic contrast-enhanced MRI for prostate cancer localization.[J].2009,82(974).
[17]Hambrock T,Barentsz JO,Somford DM,etc.Diffusion and perfusion MR imaging of the prostate.[J].2008,16(4).
[18]Chang SD,Chen H,Goldenberg SL,etc.Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology.[J].2006,24(1).
[19]Roberts C,Parker GJ,Buckley DL,etc.Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging--initial experience.[J].2004,233(3).
[20]Engelbrecht MR,van der Graaf M,van Dorsten FA,etc.Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.[J].2004,20(2).
[21]Rabe J,van Kaick G,Merkle J,etc.Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?[J].2004,14(2).
[22]Brix G,Knopp MV,Port RE.Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors.[J].2001,45(6).
[23]Rofsky NM,Lenkinski RE,McMahon CJ,etc.Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate cancer.[J].2009,17(2).
[24]P S, Tofts,G, Brix,D L, Buckley,etc.Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.[J].1999,10(3).
[25]Christian Stief,Karim Touijer,Alessandro Sciarra,etc.Functional Magnetic Resonance Imaging in Prostate Cancer[J].2009,55(4).
[26]Buckley DL.Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI.[J].2002,47(3).
[27]M K, Brawer,R E, Deering,M, Brown,etc.Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity.[J].1994,73(3).
[28]J, Folkman.Tumor angiogenesis: therapeutic implications.[J].1971,285.
[29]P S, Tofts.Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.[J].1900,7(1).
[30]Pisani P,Ferlay J,Parkin DM,etc.Global cancer statistics, 2002.[J].2005,55(2).
[31]Zelhof B,Liney GP,Lowry M.Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.[J].2009,44(9).
[32]Knopp MV,Dwyer AJ,Choyke PL.Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.[J].2003,17(5).
[33]H F, Dvorak,L F, Brown,M, Detmar,etc.Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.[J].1995,146.